Top

Published in:

01-08-2016 | Clinical Review

Diagnosis and treatment of microscopic colitis

Authors: Ryuichi Okamoto, Mariko Negi, Syohei Tomii, Yoshinobu Eishi, Mamoru Watanabe

Published in: Clinical Journal of Gastroenterology | Issue 4/2016

Abstract

Microscopic colitis (MC) designates two types of chronic diarrhea diseases, which are lymphocytic colitis and collagenous colitis. The prevalence of microscopic colitis is increasing in both Western and Eastern countries, possibly due to the high incidence of colonoscopic survey in chronic diarrhea patients. Although the overall prognosis of MC patients is mostly good, it should be noted that appropriate diagnosis and choice of treatment is required to assure a good clinical outcome for MC patients. Also, a certain population of MC patients may take a severe and refractory clinical course, and thus require advanced clinical care using medications supported by less evidence. In this review, we would like to feature the essential points regarding the diagnosis of MC, and also describe the current standard of treatments for MC patients. In addition, we would like to add some findings from the national survey and research carried out in Japan, to compare those data with the western countries.

Lindström CG. “Collagenous colitis” with watery diarrhoea–a new entity? Pathol Eur. 1976;11:87–9.PubMed

Read NW, Krejs GJ, Read MG. Santa Ana CA, Morawski SG, Fordtran JS. Chronic diarrhea of unknown origin. Gastroenterology. 1980;78:264–71.PubMed

Pardi DS, Kelly CP. Microscopic Colitis. Gastroenterology. 2011;140:1155–65.CrossRefPubMed

Münch A, Aust D, Bohr J, Bonderup O, Bañares FF, Hjortswang H, et al. Microscopic colitis: current status, present and future challenges. J Crohns Colitis. 2012;6:932–45.CrossRefPubMed

Fernández-Bañares F, Casanova MJ, Arguedas Y, Beltrán B, Busquets D, Fernández JM, et al. Current concepts on microscopic colitis: evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Aliment Pharmacol Ther. 2016;43:400–26.CrossRefPubMed

Pardi DS, Tremaine WJ, Carrasco-Labra A. American Gastroenterological Association Institute Technical Review on the Medical Management of Microscopic Colitis. Gastroenterology. 2016;150(247–274):e11.PubMed

Gentile NM, Khanna S, Loftus EV, Smyrk TC, Tremaine WJ, Harmsen WS, et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin. Gastroenterol. Hepatol. 2014;12:838–42.CrossRefPubMed

Wickbom A, Bohr J, Eriksson S, Udumyan R, Nyhlin N, Tysk C. Stable incidence of collagenous colitis and lymphocytic colitis in Örebro, Sweden, 1999–2008: a continuous epidemiologic study. Inflamm Bowel Dis. 2013;19:2387–93.CrossRefPubMed

Park YS, Baek DH, Kim WH, Kim JS, Yang S-K, Jung S-A, et al. Clinical Characteristics of Microscopic Colitis in Korea: prospective Multicenter Study by KASID. Gut Liver. 2011;5:181.CrossRefPubMedPubMedCentral

10.

Watanabe M, Okamoto R. Annual report of Practical Research Project for Rare/Intractable Diseases, Japanese Ministry of Health, Labor and Welfare [Internet]. Mamoru Watanabe; 2012. Available from: http://iss.ndl.go.jp/books/R100000002-I023582991-00. Accessed 1 Apr 2013

11.

Horita K, Koyama H, Miyata Y, Tomori A, Takahashi A, Kitamura Y. Mansei gerishou ni okeru microscopic colitis no hindo: honpou ni okeru daichou naishikyouka randamu seiken wo mochiita sokyuuteki kenkyuukekka. Shoukaki Naishikyou [Internet]. 2008;20:1357–61. Available from: http://search.jamas.or.jp/link/bc/20080909110032. Accessed 17 Dec 2011

12.

Masclee GMC, Coloma PM, Kuipers EJ, Sturkenboom MCJM. Incidence of microscopic colitis in relation to the number of colonoscopies over time. Am J Gastroenterol. 2015;110:1246–7.CrossRefPubMed

13.

Turner K, Genta RM, Sonnenberg A. Ethnic Distribution of Microscopic Colitis in the United States. Inflamm Bowel Dis. 2015;21:2634–9.CrossRefPubMed

14.

Veress B, Löfberg R, Bergman L. Microscopic colitis syndrome Gut. 1995;36:880–6.PubMed

15.

Järnerot G, Tysk C, Bohr J, Eriksson S. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995;109:449–55.CrossRefPubMed

16.

Kumawat AK, Strid H, Tysk C, Bohr J, Hörnquist EH. Microscopic colitis patients demonstrate a mixed Th17/Tc17 and Th1/Tc1 mucosal cytokine profile. Mol Immunol. 2013;55:355–64.CrossRefPubMed

17.

Fischer H, Holst E, Karlsson F, Benoni C, Toth E, Olesen M, et al. Altered microbiota in microscopic colitis. Gut. 2015;64:1185–6.CrossRefPubMedPubMedCentral

18.

Pisani LF, Tontini GE, Vecchi M, Pastorelli L. Microscopic colitis: what do we know about pathogenesis? Inflamm Bowel Dis. 2016;22:450–8.CrossRefPubMed

19.

Okamoto R, Watanabe M. Role of epithelial cells in the pathogenesis and treatment of inflammatory bowel disease. J Gastroenterol. 2016;51:11–21.CrossRefPubMed

20.

Carrasco A, Esteve M, Salas A, Pedrosa E, Rosinach M, Aceituno M, et al. Immunological Differences between Lymphocytic and Collagenous Colitis. J Crohns Colitis. 2016; jjw058.

21.

Mellander M-R, Ekbom A, Hultcrantz R, Löfberg R, Öst Å, Björk J. Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis. Scand J Gastroenterol. 2016;51:556–62.CrossRefPubMed

22.

Tong J, Zheng Q, Zheng Q, Zhang C, Lo R, Shen J, et al. Incidence, prevalence, and temporal trends of microscopic colitis: a systematic review and meta-analysis. Am. J. Gastroenterol. 2015; 110:265–76–quiz277.

23.

Bonderup OK, Fenger-Grøn M, Wigh T, Pedersen L, Nielsen GL. Drug exposure and risk of microscopic colitis: a nationwide Danish case-control study with 5751 cases. Inflamm Bowel Dis. 2014;20:1702–7.CrossRefPubMed

24.

Verhaegh BPM, de Vries F, Masclee AAM, Keshavarzian A, de Boer A, Souverein PC, et al. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:1004–13.CrossRefPubMed

25.

Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis—proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005;22:277–84.CrossRefPubMed

26.

Masclee GMC, Coloma PM, Kuipers EJ, Sturkenboom MCJM. Increased risk of microscopic colitis with use of proton pump inhibitors and non-steroidal anti-inflammatory drugs. Am J Gastroenterol. 2015;110:749–59.CrossRefPubMed

27.

Umeno J, Esaki M, Nuki Y, Kim H, Kitazono T, Matsumoto T. Letter: lansoprazole consumption is more common in Japanese patients with collagenous colitis. Aliment Pharmacol Ther. 2013;38:208–9.CrossRefPubMed

28.

Sikander A, Sinha SK, Prasad KK, Rana SV. Association of Serotonin Transporter Promoter Polymorphism (5-HTTLPR) with Microscopic Colitis and Ulcerative Colitis. Dig Dis Sci. 2015;60:887–94.CrossRefPubMed

29.

Roth B, Gustafsson RJ, Jeppsson B, Manjer J, Ohlsson B. Smoking and alcohol habits in relation to the clinical picture of women with microscopic colitis compared to controls. BMC Womens Health. 2014;14:16.CrossRefPubMedPubMedCentral

30.

Fernández-Bañares F, de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, et al. Impact of current smoking on the clinical course of microscopic colitis. Inflamm Bowel Dis. 2013;19:1470–6.CrossRefPubMed

31.

Chande N, Driman DK, Reynolds RPE. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol. 2005;40:343–7.CrossRefPubMed

32.

Kanıtez NA, Toz B, Güllüoğlu M, Erer B, Esen BA, Omma A, et al. Microscopic colitis in patients with Takayasu’s arteritis: a potential association between the two disease entities. Clin. Rheumatol. 2016;1–5. doi:10.1007/s10067-015-3149-x

33.

Fernández-Bañares F, de Sousa MR, Salas A, Beltrán B, Piqueras M, Iglesias E, et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013;19:411–7.CrossRefPubMed

34.

Macaigne G, Lahmek P, Locher C, Lesgourgues B, Costes L, Nicolas MP, et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. Am J Gastroenterol. 2014;109:1461–70.CrossRefPubMed

35.

Nguyen GC, Smalley WE, Vege SS, Carrasco-Labra A, Clinical Guidelines Committee. American Gastroenterological Association Institute Guideline on the Medical Management of Microscopic Colitis. Gastroenterology. 2016;150:242–6–quize17–8.

36.

Park HS, Han DS, Ro YO, Eun CS, Yoo KS. Does lymphocytic colitis always present with normal endoscopic findings? Gut Liver. 2015;9:197–201.CrossRefPubMed

37.

Yung DE, Koulaouzidis A, Fineron P, Plevris JN. Microscopic colitis: a misnomer for a clearly defined entity? Endoscopy. 2015;47:754–7.CrossRefPubMed

38.

Bromberg DJ, Reed J, Gill JA. Microscopic colitis that is not so microscopic. Int J Colorectal Dis. Springer Berlin Heidelberg; 2016; 31:723–4.

39.

Shimizu S, Daitchou shikkan NOW. Mutou T, editor. Nihon medical center. 2012;2012:34–7.

40.

Umeno J, Matsumoto T, Nakamura S, Jo Y, Yada S, Hirakawa K, et al. Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis. Gastrointest Endosc. 2008;67:1185–91.CrossRefPubMed

41.

van Eijk RLA, Bac DJ. Mucosal tears and colonic perforation in a patient with collagenous colitis. Endoscopy. 2014; 46 Suppl 1 UCTN:E64–4.

42.

Rasmussen J, Engel PJH, Wildt S, Fiehn A-MK, Munck LK. The Temporal Evolution of Histological Abnormalities in Microscopic Colitis. J Crohns Colitis. 2016; 10:262–8.

43.

Daichou Tanaka M, Shikkan NOW. Mutou T, editor. Nihon medical center. 2012;2012:43–51.

44.

Müller S, Neureiter D, Stolte M, Verbeke C, Heuschmann P, Kirchner T, et al. Tenascin: a sensitive and specific diagnostic marker of minimal collagenous colitis. Virchows Arch. 2001;438:435–41.CrossRefPubMed

45.

Fiehn A-MK, Engel U, Holck S, Munck LK, Engel PJH. CD3 immunohistochemical staining in diagnosis of lymphocytic colitis. Hum Pathol 2016; 48:25–31.

46.

von Arnim U, Wex T, Ganzert C, Schulz C, Malfertheiner P. Fecal calprotectin: a marker for clinical differentiation of microscopic colitis and irritable bowel syndrome. Clin Exp Gastroenterol. 2016;9:97–103.CrossRef

47.

Wagner M, Stridsberg M, Peterson CGB, Sangfelt P, Lampinen M, Carlson M. Increased fecal levels of chromogranin A, chromogranin B, and secretoneurin in collagenous colitis. Inflammation. 2013;36:855–61.CrossRefPubMed

48.

Esteve M, Mahadevan U, Sainz E, Rodriguez E, Salas A, Fernández-Bañares F. Efficacy of anti-TNF therapies in refractory severe microscopic colitis. J Crohns Colitis. 2011;5:612–8.CrossRefPubMed

49.

Fernández-Bañares F, Zabana Y, Aceituno M, Ruiz L, Salas A, Esteve M. Prevalence and natural history of microscopic colitis: a population-based study with long-term clinical follow-up in Terrassa, Spain. J Crohns Colitis. 2016. doi:10.1093/ecco-jcc/jjw037

50.

O’Brien BH, McClymont K, Brown I. Collagenous ileitis: a study of 13 cases. Am J Surg Pathol. 2011;35:1151–7.CrossRefPubMed

51.

Arnason T, Brown IS, Goldsmith JD, Anderson W, O’Brien BH, Wilson C, et al. Collagenous gastritis: a morphologic and immunohistochemical study of 40 patients. Mod Pathol. 2015;28:533–44.CrossRefPubMed

52.

Miehlke S, Madisch A, Karimi D, Wonschik S, Kuhlisch E, Beckmann R, et al. Budesonide is effective in treating lymphocytic colitis: a randomized double-blind placebo-controlled study. Gastroenterology 2009;136:2092–100CrossRefPubMed

53.

Münch A, Bohr J, Miehlke S, Benoni C, Olesen M, Öst Å, et al. Low-dose budesonide for maintenance of clinical remission in collagenous colitis: a randomised, placebo-controlled, 12-month trial. Gut 2016;65:47–56CrossRefPubMed

54.

Colussi D, Salari B, Stewart KO, Lauwers GY, Richter JR, Chan AT, Ricciardiello L, Khalili H. Clinical characteristics and patterns and predictors of response to therapy in collagenous and lymphocytic colitis. Scand J Gastroenterol. 2015;50(11):1382–8. doi:10.3109/00365521.2015.1050692 CrossRefPubMedPubMedCentral

55.

Veress B, Löfberg R, Bergman L. Microscopic colitis syndrome. Gut. 1995;36(6):880–6.CrossRefPubMedPubMedCentral

Title: Diagnosis and treatment of microscopic colitis
Authors: Ryuichi Okamoto
Mariko Negi
Syohei Tomii
Yoshinobu Eishi
Mamoru Watanabe
Publication date: 01-08-2016
Publisher: Springer Japan
Published in: Clinical Journal of Gastroenterology / Issue 4/2016
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI: https://doi.org/10.1007/s12328-016-0656-5

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Diagnosis and treatment of microscopic colitis

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2016

Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma

Idiopathic hypereosinophilic syndrome presenting with hepatitis and achalasia

Cholangiolocellular carcinoma with rapid progression initially showing abnormally elevated serum alfa-fetoprotein

A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?

Histological features of mixed neuroendocrine carcinoma and hepatocellular carcinoma in the liver: a case report and literature review

Systemic immunoglobulin light-chain amyloidosis presenting hematochezia as the initial symptom

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page